Limits of Animal Models in Cancer Chemotherapy
In animal models used in cancer chemotherapy, there is a low variability in terms of sensitivity of cancer cells in vitro, plasma levels of anticancer drugs, and interhost immune responses. In contrast, human tumors (e.g., ovarian carcinoma) show much greater variability. It is suggested that greater attention should be given to the study of the variables which distinguish the clinical setting from the animal models.
KeywordsSarcoma Peri Adriamycin Fibrosarcoma
Unable to display preview. Download preview PDF.
- 6.Piazza E, Donelli MG, Broggini M, Sessa C, Natale N, Ottolenghi L, Marsoni S, Libretti A, Mangioni C, Morasca L (to be published) Early phase pharmacokinetics of adriamycin in plasma of cancer patients during single or multidrug therapy. Cancer Treat RepGoogle Scholar